Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects
NCT07580703Phase 1Recruiting
- Sponsor
- Eli Radiopharma
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of flortaucipir in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Eli Radiopharma. Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events. Started Apr 2026; status: recruiting.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07580703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07580703.